SPAC17A5.05c Antibody

What is SPAC17A5.05c and why is it important in S. pombe research?

SPAC17A5.05c is a specific gene in Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. While detailed characterization data is limited in the current literature, antibodies against this target are valuable tools for researchers studying S. pombe cellular processes. Fission yeast serves as an excellent model organism for understanding fundamental eukaryotic cellular mechanisms because of its relatively simple genome, ease of genetic manipulation, and conservation of many basic cellular processes with higher eukaryotes including humans. Using SPAC17A5.05c antibodies allows researchers to track the expression, localization, and interactions of this protein in various experimental conditions .

How should I validate SPAC17A5.05c antibody specificity before experiments?

Methodological approach to validation:

• Western blot analysis: Run samples from wild-type S. pombe alongside a SPAC17A5.05c deletion mutant (if available) to confirm specificity.

• Immunoprecipitation followed by mass spectrometry: This identifies whether the antibody is pulling down the intended target and any cross-reactive proteins.

• Immunofluorescence microscopy: Compare staining patterns between wild-type and deletion strains.

• Peptide competition assay: Pre-incubate the antibody with purified SPAC17A5.05c peptide before application to confirm signal reduction.

A comprehensive validation should include at least two different methods to confirm specificity. Document the validation results thoroughly before proceeding with experiments, as antibody specificity is crucial for reliable interpretation of results .

What experimental controls should I include when using SPAC17A5.05c antibody?

For rigorous experimental design with SPAC17A5.05c antibody, include these controls:

These controls help distinguish between specific signal and experimental artifacts, enabling confident interpretation of results and enhancing reproducibility .

What is the recommended fixation method for immunofluorescence with SPAC17A5.05c antibody?

When performing immunofluorescence with SPAC17A5.05c antibody in S. pombe cells, fixation methodology significantly impacts epitope preservation and accessibility. For optimal results, consider these methodological approaches:

• Paraformaldehyde fixation (4%): Preserves cellular architecture while maintaining many epitopes. Incubate cells for 15-20 minutes at room temperature.

• Methanol fixation: Often preferred for yeast cell wall penetration. Fix cells for 10 minutes at -20°C.

• Combined approach: For some applications, a brief (5 min) paraformaldehyde fixation followed by methanol treatment improves antibody accessibility.

Always include enzyme digestion of the cell wall (using zymolyase or lysing enzymes) after fixation to enhance antibody penetration. Optimization of fixation conditions is recommended for each specific experimental setup, as the SPAC17A5.05c epitope accessibility may vary with different fixation protocols .

How can I implement SPAC17A5.05c antibody in chromatin immunoprecipitation (ChIP) experiments?

Methodological guidance for ChIP with SPAC17A5.05c antibody:

• Cross-linking optimization: For S. pombe, use 1% formaldehyde for 15 minutes at room temperature. The efficiency of cross-linking directly impacts ChIP success.

• Chromatin fragmentation: Sonicate to achieve fragments of 200-500bp. Test multiple sonication conditions (time, amplitude, duty cycle) to determine optimal parameters.

• Antibody incubation parameters:

  • Concentration: Start with 2-5μg of SPAC17A5.05c antibody per reaction

  • Incubation time: 16 hours at 4°C with rotation

  • Pre-clearing: Implement with protein A/G beads to reduce background

• Washing stringency gradient: Employ increasingly stringent wash buffers to preserve specific interactions while eliminating background.

• Validation approaches:

  • Perform parallel ChIP with different antibody lots

  • Include IgG control to establish background enrichment levels

  • Use spike-in controls for normalization

  • Confirm enrichment at predicted binding sites via qPCR before proceeding to sequencing

The critical factors affecting ChIP success with SPAC17A5.05c antibody include antibody affinity, epitope accessibility in cross-linked chromatin, and washing stringency. Optimization of these parameters is essential for generating reproducible results .

What strategies can resolve contradictory results when using SPAC17A5.05c antibody in different experimental systems?

When facing contradictory results with SPAC17A5.05c antibody across different experimental systems, implement this systematic troubleshooting approach:

• Antibody validation reassessment:

  • Perform epitope mapping to identify the specific regions recognized

  • Investigate lot-to-lot variations through side-by-side testing

  • Evaluate antibody performance in multiple applications (Western blot, IP, IF)

• Experimental parameter analysis:

  • Document all buffer compositions, incubation times, and temperatures

  • Analyze sample preparation variations (lysis methods, detergent types, protease inhibitors)

  • Assess the impact of cell culture conditions on protein expression levels

• Species and strain considerations:

  • Sequence compare SPAC17A5.05c across S. pombe strains used in different labs

  • Check for post-translational modifications that might affect epitope recognition

• Methodological reconciliation:

  • Design experiments that bridge methodologies (e.g., confirm IF results with biochemical fractionation)

  • Implement orthogonal techniques to verify results (mass spectrometry, CRISPR tagging)

• Biological context integration:

  • Analyze cell cycle-dependent expression/localization

  • Assess stress or environmental factors affecting results

By systematically addressing these factors, researchers can identify the source of discrepancies and develop a unified understanding of SPAC17A5.05c behavior across experimental systems .

How should I optimize co-immunoprecipitation protocols for detecting SPAC17A5.05c protein-protein interactions?

For detecting protein-protein interactions involving SPAC17A5.05c, implement this methodological optimization strategy:

• Lysis buffer optimization:

  • Test multiple detergent types (NP-40, Triton X-100, CHAPS) at varying concentrations

  • Adjust salt concentration (150-500mM) to balance preservation of interactions versus background reduction

  • Add stabilizing agents (glycerol 5-10%) to maintain complex integrity

• Cross-linking considerations:

  • Implement reversible cross-linking (DSP or formaldehyde at 0.1-1%) for capturing transient interactions

  • Optimize cross-linker concentration through titration experiments

  • Ensure complete reversal before SDS-PAGE analysis

• Antibody implementation strategy:

  • Compare direct IP (antibody-conjugated beads) vs. indirect methods (antibody + protein A/G beads)

  • Test different antibody:lysate ratios to determine optimal concentration

  • Consider pre-clearing lysates with isotype control antibody

• Washing protocol development:

  • Implement stringency gradient washing (increasing salt/detergent concentrations)

  • Optimize wash number and duration based on signal:noise ratio

  • Consider detergent switching in sequential washes

• Elution method selection:

  • Compare specific peptide elution vs. denaturing conditions

  • For interaction mapping, test native elution conditions

• Detection optimization:

  • Implement reciprocal IP (IP with antibody against suspected interacting partner)

  • Confirm interactions using proximity ligation assays as orthogonal validation

The key factors affecting co-immunoprecipitation success include preserving physiological interactions while minimizing non-specific associations and having sufficient sensitivity to detect possibly low-abundance complexes .

What approaches can identify post-translational modifications of SPAC17A5.05c using antibody-based techniques?

Comprehensive strategy for identifying post-translational modifications (PTMs) of SPAC17A5.05c:

• Modification-specific antibody screening:

  • Test commercially available pan-antibodies against common PTMs (phosphorylation, acetylation, ubiquitination)

  • Perform immunoprecipitation with SPAC17A5.05c antibody followed by Western blotting with PTM-specific antibodies

• Mass spectrometry workflow implementation:

  • Large-scale immunoprecipitation using SPAC17A5.05c antibody

  • Implement enrichment strategies for specific modifications (TiO2 for phosphopeptides, ubiquitin remnant antibodies)

  • Analyze by LC-MS/MS with HCD and ETD fragmentation methods

  • Apply label-free quantification or SILAC for comparative analysis

• Site-specific validation methods:

  • Generate phospho-site specific antibodies for confirmed sites

  • Implement site-directed mutagenesis to confirm functional significance

  • Use lambda phosphatase treatment to confirm phosphorylation

• Dynamic modification analysis:

  • Time-course experiments following stimulation/stress

  • Cell cycle synchronization to identify cell cycle-dependent modifications

  • Inhibitor studies to identify responsible kinases/enzymes

• Bioinformatic prediction integration:

  • Compare experimental results with algorithm-predicted modification sites

  • Analyze conservation of modification sites across related species

This comprehensive approach combines antibody-based detection with advanced proteomic techniques to create a detailed map of SPAC17A5.05c post-translational modifications and their biological significance .

How can I quantitatively analyze SPAC17A5.05c expression levels across different experimental conditions?

Methodological framework for quantitative analysis of SPAC17A5.05c expression:

This framework enables reliable quantification of SPAC17A5.05c across experimental conditions while accounting for technical variables and biological heterogeneity .

What are the most effective strategies for troubleshooting non-specific binding with SPAC17A5.05c antibody?

Comprehensive troubleshooting strategy for non-specific binding:

• Buffer optimization protocol:

  • Implement titration series of blocking agents (BSA 1-5%, milk 1-10%, normal serum 2-10%)

  • Test detergent concentration series (Tween-20, 0.05-0.3%)

  • Evaluate salt concentration impact (150-500mM NaCl)

  • Assess the effect of carrier proteins (0.1-1% gelatin or casein)

• Antibody implementation parameters:

  • Perform antibody dilution series to identify optimal concentration

  • Test reduced incubation times and temperatures

  • Implement pre-adsorption with non-specific proteins

  • Compare different antibody lots for variation in specificity

• Sample preparation refinement:

  • Evaluate multiple lysis buffers for background reduction

  • Test pre-clearing samples with protein A/G beads

  • Assess the impact of reducing agents on epitope accessibility

  • Implement additional wash steps with increasing stringency

• Cross-reactivity analysis:

  • Perform peptide competition assays with predicted cross-reactive epitopes

  • Test antibody performance in knockout/knockdown systems

  • Implement epitope mapping to identify non-specific recognition regions

• Application-specific interventions:

  • For Western blot: Increase transfer efficiency, optimize membrane type

  • For IF: Test different fixation methods, implement antigen retrieval

  • For IP: Modify bead type, washing stringency, and elution conditions

  • For ELISA: Optimize coating concentration and blocking efficiency

This systematic approach addresses the multiple variables that can contribute to non-specific binding, enabling researchers to identify and eliminate sources of background signal .

How should I design experiments to determine the optimal concentration of SPAC17A5.05c antibody for different applications?

Methodological framework for antibody titration across applications:

• Western blot titration design:

  • Prepare a serial dilution series of antibody (1:500 to 1:10,000)

  • Maintain constant protein loading and all other variables

  • Analyze signal-to-noise ratio at each concentration

  • Plot signal intensity versus antibody concentration to identify saturation point

  • Determine the minimum concentration yielding acceptable signal (typically 50-80% of maximum)

• Immunofluorescence optimization:

  • Implement a matrix approach testing antibody dilutions (1:100 to 1:2,000) against multiple fixation methods

  • Quantify both signal intensity and background levels

  • Calculate specific-to-nonspecific signal ratio for each condition

  • Analyze subcellular localization consistency across concentrations

• Immunoprecipitation efficiency analysis:

  • Test antibody amounts ranging from 1-10μg per reaction

  • Analyze both immunoprecipitation efficiency and non-specific binding

  • Implement sequential IPs to determine saturation point

  • Assess the impact of bead type and volume on optimal antibody concentration

• ChIP-sequencing parameter optimization:

  • Perform antibody titration (2-10μg per reaction)

  • Analyze enrichment at known or predicted binding sites

  • Evaluate signal-to-input ratio and peak quality metrics

  • Calculate library complexity at different antibody concentrations

• Cross-application analysis:

  • Compare optimal concentrations across applications

  • Document batch-to-batch variation in optimal concentration

  • Establish internal reference standards for future experiments

This systematic approach yields application-specific optimal antibody concentrations while providing insights into antibody performance characteristics across experimental contexts .

What techniques can differentiate between specific signal and background when using SPAC17A5.05c antibody in immunofluorescence microscopy?

Advanced methodological approaches to distinguish specific signal from background:

• Genetic validation methods:

  • Compare staining patterns between wild-type and SPAC17A5.05c deletion strains

  • Implement CRISPR-tagged endogenous protein for co-localization analysis

  • Use RNAi-mediated knockdown to confirm signal reduction parallels protein depletion

• Signal authentication techniques:

  • Perform peptide competition assays with blocking peptides at multiple concentrations

  • Implement fluorescence resonance energy transfer (FRET) with secondary detection system

  • Test multiple antibodies targeting different epitopes of SPAC17A5.05c

  • Compare native versus overexpression systems for localization consistency

• Advanced microscopy approaches:

  • Implement super-resolution techniques (STED, PALM, STORM) for detailed localization analysis

  • Use spectral unmixing to separate autofluorescence from specific signal

  • Apply deconvolution algorithms to enhance signal-to-noise ratio

  • Implement airyscan or spinning disk confocal for improved resolution

• Quantitative analysis implementation:

  • Establish intensity thresholds based on negative controls

  • Perform line-scan analysis across cellular compartments

  • Implement colocalization analysis with known markers

  • Apply machine learning algorithms for unbiased pattern recognition

• Protocol optimization strategies:

  • Test multiple permeabilization methods for optimal epitope accessibility

  • Implement antigen retrieval techniques adapted from histology

  • Optimize fixation timing to preserve epitope integrity

  • Test background-reducing additives (e.g., fish gelatin, normal serum)

This comprehensive approach combines genetic controls, advanced microscopy techniques, and quantitative analysis to confidently distinguish specific SPAC17A5.05c signal from background or artifacts .

How can SPAC17A5.05c antibody be employed in spatial proteomics workflows?

Methodological framework for integrating SPAC17A5.05c antibody in spatial proteomics:

• Proximity labeling approaches:

  • Engineer SPAC17A5.05c fusion with BioID or APEX2 proximity labeling enzymes

  • Compare proximity interactome with conventional immunoprecipitation data

  • Validate interactions through reciprocal labeling experiments

  • Combine with SPAC17A5.05c antibody for orthogonal confirmation

• Subcellular fractionation integration:

  • Implement biochemical fractionation protocols optimized for S. pombe

  • Use SPAC17A5.05c antibody to track protein distribution across fractions

  • Combine with markers for cellular compartments for normalized quantification

  • Apply proteomics analysis to fractions enriched for SPAC17A5.05c

• Spatial transcriptomics correlation:

  • Implement IF with SPAC17A5.05c antibody alongside RNA-FISH

  • Analyze spatial correlation between protein localization and mRNA distribution

  • Apply computational analysis to identify spatial organization patterns

  • Implement live-cell imaging to track dynamic changes

• Super-resolution mapping:

  • Apply PALM/STORM with SPAC17A5.05c antibody for nanoscale localization

  • Implement expansion microscopy for physical magnification of structures

  • Correlate with electron microscopy through CLEM approaches

  • Develop quantitative spatial statistics for pattern analysis

• Computational integration:

  • Implement machine learning algorithms for pattern recognition

  • Develop 3D reconstructions from Z-stack acquisitions

  • Apply spatial statistics to quantify clustering and co-localization

  • Integrate with protein interaction databases for functional context

This comprehensive framework enables detailed characterization of SPAC17A5.05c spatial distribution and context within cellular architecture, providing insights into its functional organization .

What considerations are important when developing a phospho-specific antibody against SPAC17A5.05c?

Methodological roadmap for phospho-specific antibody development:

• Phosphorylation site identification and selection:

  • Analyze existing phosphoproteomic datasets for SPAC17A5.05c

  • Implement computational prediction of phosphorylation sites

  • Prioritize sites based on conservation across species

  • Consider functional domains and structural accessibility

  • Focus on regulatory sites with predicted biological significance

• Phosphopeptide design parameters:

  • Optimal length: 10-15 amino acids with phosphorylation site centrally positioned

  • Analyze peptide solubility and immunogenicity characteristics

  • Implement strategies to enhance specificity (variable regions flanking conserved site)

  • Consider carrier protein conjugation methods (KLH, BSA)

  • Design corresponding non-phosphorylated peptide for negative selection

• Immunization and screening strategy:

  • Implement multiple-animal protocols to increase success probability

  • Design ELISA screening with phosphorylated vs. non-phosphorylated peptides

  • Develop dot-blot analysis with peptide dilution series

  • Test reactivity against recombinant SPAC17A5.05c with and without phosphatase treatment

• Validation methodology:

  • Generate phosphomimetic and phospho-null mutants of SPAC17A5.05c

  • Test antibody specificity under conditions that modulate phosphorylation

  • Implement lambda phosphatase controls in Western blot analysis

  • Validate specificity through immunoprecipitation followed by mass spectrometry

• Characterization requirements:

  • Determine detection limits across applications

  • Test cross-reactivity with related phosphoproteins

  • Assess epitope accessibility in different experimental conditions

  • Document specificity parameters in detailed validation reports

This systematic approach addresses the complex challenges of developing highly specific phospho-antibodies while establishing rigorous validation criteria to ensure experimental reliability .

How can I implement mass spectrometry-based validation of SPAC17A5.05c antibody specificity?

Comprehensive mass spectrometry validation methodology:

• Immunoprecipitation-mass spectrometry workflow:

  • Perform large-scale immunoprecipitation with SPAC17A5.05c antibody from native lysates

  • Implement parallel IPs with isotype control and alternative SPAC17A5.05c antibody

  • Process samples through gel separation followed by in-gel digestion

  • Apply high-resolution LC-MS/MS analysis with extended gradients for deep coverage

  • Implement target-decoy approach for false discovery rate control

• Data analysis framework:

  • Calculate enrichment factors for identified proteins (IP vs. control)

  • Implement statistical filtering (p-value, FDR) for high-confidence identifications

  • Analyze sequence coverage of SPAC17A5.05c across multiple experiments

  • Map identified peptides to protein domains and structural features

  • Evaluate detection of known interactors as secondary validation

• Cross-linking mass spectrometry integration:

  • Apply protein cross-linking before immunoprecipitation

  • Identify cross-linked peptides to map antibody binding regions

  • Compare experimental epitope mapping with predicted epitopes

  • Analyze accessibility of identified epitopes in protein's tertiary structure

• Targeted proteomics approach:

  • Develop parallel reaction monitoring (PRM) or multiple reaction monitoring (MRM) assays

  • Quantify SPAC17A5.05c across subcellular fractions

  • Correlate MS-based quantification with antibody-based detection

  • Implement AQUA peptides for absolute quantification

• Competitive binding analysis:

  • Pre-incubate antibody with synthetic peptides covering different regions

  • Analyze mass spectrometry profiles for shifts in binding patterns

  • Identify peptides that effectively compete for antibody binding

This comprehensive approach provides definitive validation of antibody specificity while generating detailed characterization of epitope recognition and potential cross-reactivity profiles .

How can SPAC17A5.05c antibody be used to investigate protein function during the S. pombe cell cycle?

Methodological framework for cell cycle studies using SPAC17A5.05c antibody:

• Synchronization methodology:

  • Implement lactose gradient centrifugation for early G2 selection

  • Apply hydroxyurea block-and-release for S-phase synchronization

  • Use cold-sensitive cdc25 mutants for G2/M boundary arrest

  • Confirm synchronization efficiency through flow cytometry and septation index

• Temporal expression analysis:

  • Collect samples at 10-minute intervals across the cell cycle

  • Perform quantitative Western blotting with SPAC17A5.05c antibody

  • Normalize to total protein and loading controls

  • Plot expression dynamics relative to cell cycle progression markers

  • Analyze protein half-life through cycloheximide chase experiments

• Dynamic localization studies:

  • Implement time-lapse microscopy with fixed-cell immunofluorescence

  • Analyze colocalization with cell cycle-regulated structures

  • Quantify nuclear-cytoplasmic distribution changes

  • Correlate localization changes with cell cycle transitions

  • Apply 3D reconstruction to analyze spatial reorganization

• Post-translational modification dynamics:

  • Use SPAC17A5.05c antibody immunoprecipitation followed by PTM-specific antibodies

  • Implement phosphatase inhibition strategies for phosphorylation analysis

  • Correlate modifications with cell cycle kinase activities

  • Test modification-deficient mutants for cell cycle phenotypes

• Protein interaction network dynamics:

  • Perform time-resolved co-immunoprecipitation across cell cycle

  • Implement BioID or APEX2 proximity labeling with time-point sampling

  • Analyze temporal changes in interaction networks

  • Correlate with functional changes and cell cycle transitions

This integrated approach reveals the dynamics of SPAC17A5.05c expression, localization, modification, and interactions throughout the cell cycle, providing insights into its regulatory mechanisms and functions .

What are the best practices for using SPAC17A5.05c antibody in conjunction with CRISPR-Cas9 gene editing in S. pombe?

Methodological integration of SPAC17A5.05c antibody with CRISPR-Cas9 experiments:

• Epitope tagging validation strategy:

  • Design CRISPR-mediated epitope tagging of endogenous SPAC17A5.05c

  • Validate tagged protein expression levels match wild-type using SPAC17A5.05c antibody

  • Compare subcellular localization between tagged and untagged (antibody-detected) protein

  • Assess functionality through phenotypic analysis of tagged strains

• Knockout confirmation methodology:

  • Design guides targeting multiple regions of SPAC17A5.05c

  • Confirm knockout efficiency using SPAC17A5.05c antibody in Western blot and IF

  • Quantify residual protein in heterogeneous populations

  • Establish detection limits for complete knockout verification

• Domain-function analysis approach:

  • Create CRISPR-mediated domain deletions or mutations

  • Use SPAC17A5.05c antibody to confirm stable expression of truncated proteins

  • Analyze impact on localization, interactions, and modifications

  • Correlate molecular changes with phenotypic outcomes

• Functional genomics integration:

  • Implement CRISPR interference/activation to modulate SPAC17A5.05c expression

  • Measure dosage effects using quantitative analysis with SPAC17A5.05c antibody

  • Analyze threshold levels required for proper localization and function

  • Combine with high-content microscopy for phenotypic profiling

• Multiplexed analysis strategy:

  • Apply CRISPR screens targeting SPAC17A5.05c pathway components

  • Use SPAC17A5.05c antibody for downstream proteomics analysis

  • Implement synthetic genetic array analysis with CRISPR-edited strains

  • Analyze epistatic relationships through combined genetic-proteomic approach

This integrated framework maximizes the synergy between CRISPR-Cas9 genome editing and antibody-based protein analysis, enabling comprehensive functional characterization of SPAC17A5.05c and its interaction network .